ISDA: 8HEF

Deposition Date 2022-11-08

Release Date 2023-04-19

Last Version Date 2023-08-30

Entry Detail

PDB ID:

8HEF

Keywords:

VIRAL PROTEIN

Title:

The Crystal structure of deuterated S-217622 (Ensitrelvir) bound to the main protease (3CLpro/Mpro) of SARS-CoV-2

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.51 Å

R-Value Free:

0.17

R-Value Work:

0.13

R-Value Observed:

0.13

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:3C-like proteinase
Gene (Uniprot):rep
Chain IDs:A, B
Chain Length:301
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTD1 Pfam ID:PF05409 EC:2.7.7.48

Ligand Molecules

7YY

GOL

Primary Citation

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.

Yang, Y, Cao, L, Yan, M, Zhou, J, Yang, S, Xu, T, Huang, S, Li, K, Zhou, Q, Li, G, Zhu, Y, Cong, F, Zhang, H, Guo, D, Li, Y, Zhang, X.Show

Antiviral Res. 213 105586 105586 (2023)

PMID: 36997073 DOI: 10.1016/j.antiviral.2023.105586

Abstact

S-217622 (Ensitrelvir) is a reversible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3-chymotrypsin-like protease (3CLpro) inhibitor which obtained emergency regulatory approval in Japan for the treatment of SARS-CoV-2 infection on Nov 22, 2022. Herein, analogs of S-271622 with deuterium-for-hydrogen replacement were synthesized for comparison of the antiviral activities and pharmacokinetic (PK) profiles. Compared to the parent compound, C11-d2-S-217622 compound YY-278 retained in vitro activity against 3CLpro and SARS-CoV-2. X-ray crystal structural studies showed similar interactions of SARS-CoV-2 3CLpro with YY-278 and S-271622. The PK profiling revealed the relatively favorable bioavailability and plasma exposure of YY-278. In addition, YY-278, as well as S-217622, displayed broadly anti-coronaviral activities against 6 other coronaviruses that infect humans and animals. These results laid the foundation for further research on the therapeutic potential of YY-278 against COVID-19 and other coronaviral diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form